StemCell Therapy

Proposition 14 on the November ballot asks voters to approve $5.5 billion to continue funding stem cell research in California.

Supporters said the research has already lead to important medical breakthroughs, including for COVID-19 victims. Opponents said the proposition is more "shameless overpromising" with money that could be better spent elsewhere.

California voters have been though this before.

In 2004, state voters approved Proposition 71, which meant $3 billion for stem cell research and to establish the California Institute of Regenerative Medicine, or CIRM. The group's chairman and Proposition 14's financial backer, Robert Klein, said that money has lead to significant medical breakthroughs.

But now, CIRM is almost out of money, and Proposition 14 asks voters for $5.5 more for stem cell research.

"If 70 different patient advocacy organizations, from the Michael J. Fox Foundation to the American Diabetes Foundation and the American Association of Cancer Researchers all endorse us -- could they all be wrong?" Klein asked.

Longtime AIDS activist Jeff Sheehy is on the CIRM board and said residents are still paying $325 million a year for Proposition 71.

"We're going to add another $300 million on top of that -- that's two-thirds of $1 billion for stem cell research," Sheehy said. "We don't have a single FDA approved product yet."

Sheehy said taxpayer funding of stem cell research was needed back in 2004 when California was on its own, but now the feds and private industry are spending billions on it every year.

"So we're just duplicating," Sheehy said.

Marcy Darnovsky, executive director of the Center for Genetics and Society, opposes Proposition 14 because of CIRM's quote "Shameless overpromising and hype set the stage for hundreds of underregulated commercial stem cell clinics now offering unapproved treatments that have caused tumors and blindness."

"All those people who survive COVID-19, they are finding up to 50% have heart damage and other organ damage," Darnovsky said. "How are you going to regenerate those tissues? Regenerative medicine is still cell therapy."

Dr. Michael Matthay professor of critical care medicine at UCSF, said CIRM has provided grant money to help research COVID-19 treatments.

"We are using cell based therapy to reduce injury to longs from COVID-19 and to accelerate the recovery process," Matthay said.

It should be pointed out everyone interviewed for this story are in favor of stem cell research -- Darnovsky and Sheehy believe that the billions of dollars being asked of taxpayers could be better spent on education, healthcare, housing and jobs.

See the original post:
Election Guide: Here's What You Need to Know About Proposition 14 - NBC Bay Area

In a big blessing for blood cancer patients requiring stem cell therapy, the State government has established a Centre for Stem Cell and Regenerative Medicine in the Nizams Institute of Medical Sciences (NIMS). The facility will particularly help those from the lower strata of the society who cannot afford corporate medical care.

The centre was inaugurated on Friday by Health Minister Eatala Rajender in the presence of NIMS Director K. Manohar and Superintendent N. Satyanarayana. The centre will provide a ray of hope to blood cancer patients from poor families, those covered under Aarogyashri scheme, requiring stem cell therapy as they would be treated at the centre free of cost, the Minister saidafter dedicating the stem cell and molecular lab as part of the centre to the people.

With the opening of the stem cell therapy centre, NIMS has grown into one of the major hospitals in the country, Mr Rajender stated samples of blood cancer patients which were sent to Delhi for diagnosis earlier can now be done here itself. The success rate of NIMS in stem cell therapy among kidney and heart transplantation patients was very high, he said, but some services were stopped due to rise in COVID-19 cases. However, all services would be resumed within a week with the COVID spread now under control.

Stating that living with COVID-19 would be a new norm as the society was doing with dengue, viral fever, swine flu and malaria, the Minister said and asserted that as per ICMR statistics, about 40 lakh people in Telangana had developed antibodies to COVID and the fleecing of patients families by corporate hospitals in the name of plasma therapy and some costly injections was wrong.

Mr Rajender admitted that COVID treatment in NIMS had impacted the treatment of other patients, particularly those coming in emergency health conditions, and made it clear that outpatient services would be scaled up soon with OP and Critical Care blocks being set up with an investment of 250 crore. Chief Minister K. Chandrasekhar Rao would lay the foundation stone for the new blocks soon to scale up the outpatient services from 2,500 a day in the past to 5,000 a day.

Here is the original post:
Stem cell therapy for blood cancer patients at NIMS - The Hindu

Newswise CHICAGO: J. Wayne Meredith, MD, FACS, MCCM, an esteemed trauma, thoracic, and critical care surgeon from Winston-Salem, N.C., was installed this evening for a one-year term as the 101st President of the American College Surgeons (ACS). The installation occurred during the Convocation ceremony that is a highlight of the virtual ACS Clinical Congress 2020, one of the largest educational meetings of surgeons in the world.

Dr. Meredith is the Richard T. Myers Professor and Chairman, department of surgery, Wake Forest School of Medicine, Winston-Salem, and chair of surgery at Wake Forest School of Medicine since 1997. Dr. Meredith joined the faculty of Wake Forest University Health Sciences in 1987. In his years of service at Wake Forest School of Medicine, Dr. Meredith has taken on leadership roles: he served as director of surgical sciences through June 2014 and was appointed chief of clinical chairs of Wake Forest Baptist Medical Center in July 2019.

In addition to serving as the Richard T. Myers Professor and Chair, he has served 10 years as residency program director, department of surgery, Wake Forest School of Medicine. Along with serving as medical director of The Childress Institute for Pediatric Trauma, Dr. Meredith holds a cross-appointment at Wake Forest Institute for Regenerative Medicine, as well as a joint appointment as professor of pediatrics, department of pediatrics. He is chairman of the medical executive committee, a member of Wake Forests graduate medical education committee (1999present), the risk and insurance management advisory council (2002present), the faculty executive council (2002present), the cancer center oversight committee (2004present), the health system management council (2011present), and chairs the medical executive committee (2011present). He has served on the boards of North Carolina Baptist Hospital and Wake Forest Baptist Medical Center.

During his ACS presidential address, entitled Lessons Learned on the Way to this Podium, Dr. Meredith told more than 2,000 newly initiated Fellows of the American College of Surgeons numerous words of advice on having a successful and rewarding career in surgery.

A Fellow of the American College of Surgeons (FACS) since 1990, Dr. Meredith has devoted much of his expertise and energy to ACS trauma-related activities. He served as the Medical Director of ACS Trauma Programs (20062010) and Chair of the Committee on Trauma (COT) (20022006). He has chaired the COTs National Trauma Data Bank Ad Hoc Committee (19972002), the Trauma Registry Subcommittee (19942002), and continues to serve on the Verification, Review, and Consultation Committee (1996present). In addition, he has been a liaison member of the Program Committee (20022006), a member of the national faculty for Advanced Trauma Life Support (2002present), and the ACS COT representative to the American Board of Surgery (ABS) Trauma, Burns, and Critical Care Advisory Council (20052006).

Dr. Meredith is an ACS Governor at-Large (2017present) and serves on the Board of Governors Surgical Training Workgroup. He previously served on the Health Policy Advisory Council (2018).

Furthermore, Dr. Meredith has played a significant role in state-level ACS activities since joining the North Carolina Chapter of the ACS in 1991. He has served as a member of the chapters Board of Directors (1994present), as a member (1991present) and Chair (19911997) of the North Carolina COT, and North Carolina Chapter President (2005).

The College honored Dr. Meredith for his contributions to the ACS with the 2014 Distinguished Service Award (DSA), the Colleges highest honor. The Board of Regents of the ACS presented the DSA to Dr. Meredith in appreciation of his continuous and devoted service as a Fellow and in recognition of his distinctive scientific contributions in cardiovascular physiology during resuscitation, trauma registries, and trauma systems.

In addition to his previously noted service in leadership roles in ACS Trauma Programs, Dr. Meredith has been active in the field in various capacities both nationally and globally. He has been named a visiting professor or named lecturer at more than 20 institutions around the world, from Johannesburg, South Africa, to Quito, Ecuador. He serves on the editorial board of several journals, and is the author or coauthor of more than 170 scientific publications, more than 20 book chapters, and one textbook,Trauma: Contemporary Principles and Therapy.

Dr. Merediths research interests include thoracic trauma, the biomechanics of crash injury, injury severity measures, and trauma systems development. Over the course of his distinguished career, he has been awarded 10 grants for various trauma research studies. He is the principal investigator for a National Institutes of Health grant for Integrative Training in Trauma and Regenerative Medicine, as well as a joint project with Wake Forest School of Medicine and the National Highway Traffic Safety Administration that established a Crash Injury Research and Engineering Network Center of Wake Forest and Virginia Tech, Blacksburg.

Dr. Meredith has held leadership roles in many other professional organizations including president of many surgical professional societies: the Southeastern Surgical Congress, the Eastern Association for the Surgery on Trauma, the Halsted Society, the American Association for the Surgery of Trauma, and the Southern Surgical Association. He has held multiple other leadership positions, including service as director of the American Board of Surgery and the American Board of Thoracic Surgery.

Dr Meredith lives in Winston Salem with Gayle, his spouse of 46 years and constant source of inspiration and love. They have two wonderful children Russell and Amanda, aged 37 and 32.

Other ACS officers installed this evening include:

First Vice-President-Elect H. Randolph Bailey, MD, FACS, FASCRS, a respected colon and rectal surgeon who practices at the University of Texas (UT)/McGovern Medical School, Houston. Dr. Bailey is professor of surgery and emeritus program director of the UT colon and rectal surgery residency training program. He is chief, division of colon and rectal surgery, Memorial Hermann Hospital Texas Medical Center, and deputy chief of surgery, Houston Methodist Hospital.

Second Vice-President-Elect Lisa A. Newman, MD, MPH, FACS, FASCO, is director, interdisciplinary breast program; chief, division of breast surgery; and medical director, International Center for the Study of Breast Cancer Subtypes; Weill Cornell Medicine-New York Presbyterian Hospital Network, N.Y. She also is an adjunct professor of breast surgery at UT MD Anderson Cancer Center, Houston.

FACS designates that a surgeon is a Fellow of the American College of Surgeons.

# # #

About J. Wayne Meredith, MD, FACS, MCCM Dr. Meredith graduated from Emory University, Atlanta, Ga., with a bachelor of arts degree in physics. He earned his medical degree and completed his surgical training in general surgery and cardiothoracic surgery at what is now Wake Forest Baptist Medical Center, Winston-Salem, N.C. He completed his trauma/critical care fellowship as visiting assistant professor of surgery/trauma under the supervision of the late Donald D. Trunkey, MD, FACS, at Oregon Health Sciences University Hospital, Portland.

About the American College of Surgeons The American College of Surgeons is a scientific and educational organization of surgeons that was founded in 1913 to raise the standards of surgical practice and improve the quality of care for all surgical patients. The College is dedicated to the ethical and competent practice of surgery. Its achievements have significantly influenced the course of scientific surgery in America and have established it as an important advocate for all surgical patients. The College has more than 82,000 members and is the largest organization of surgeons in the world. For more information, visitwww.facs.org.

See the original post here:
Winston-Salem trauma surgeon Dr. J. Wayne Meredith installed as the 101st President of the American College of Surgeons - Newswise

Gosselies, Belgium, 5 October 2020, 7am CEST BONE THERAPEUTICS(Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, Link Health Pharma Co., Ltd (Link Health) and Shenzhen Pregene Biopharma Company, Ltd (Pregene) today announce the signing of an exclusive license agreement for the manufacturing, clinical development and commercialization of Bone Therapeutics allogeneic, off-the-shelf, bone cell therapy platform ALLOB in China (including Hong Kong and Macau), Taiwan, Singapore, South Korea, and Thailand.

Under the agreement, Bone Therapeutics is eligible to receive up to 55 million in development, regulatory and commercial milestone payments including 10 million in upfront and milestone payments anticipated in the next 24 months. Bone Therapeutics is also entitled to receive tiered double-digit royalties on annual net sales of ALLOB. Bone Therapeutics retains development and commercialization rights to ALLOB in all other geographies outside of those covered by this agreement. As a result, Bone Therapeutics will continue to concentrate on its development and commercialization plans for ALLOB in the US and Europe and novel innovative cell-based products globally.

This collaboration between Bone Therapeutics, Link Health and Pregene expands our geographic reach and demonstrates the global commercial potential of ALLOB,said Miguel Forte, MD, PhD, Chief Executive Officer of Bone Therapeutics. We already have operational experience in Asia with the Phase III clinical trial of our lead product JTA-004 in Hong Kong. We selected Link Health and Pregene to partner with us in Asia as a result of their expertise in advanced therapeutics and cell therapies, their proven track record of development and commercial implementation in Chinese and Asian markets, and Pregenes well established cell therapy manufacturing capacity. Bone Therapeutics will continue to develop the ALLOB cell therapy platform for other markets while exploring additional partnership opportunities in the U.S. and Europe.

The agreement grants Link Health and Pregene exclusive rights to clinically develop and commercialize ALLOB for the treatment of human bone disorders in Greater China, Taiwan, Singapore, South Korea, and Thailand. All rights for China will be transferred to Pregene and Link Health will gain rights for the remaining countries Bone Therapeutics will share its patented proprietary manufacturing expertise for the expansion and differentiation of bone-forming cells and has the option to sell clinical supplies to Link Health and Pregene in preparation for their clinical development of ALLOB.

This collaboration and license agreement for Bone Therapeutics ALLOB provides a strong addition to our pipeline. ALLOB has demonstrated the potential to reduce the recovery time and stimulate bone growth for a variety of bone conditions, and to have a considerable impact on patients lives,said Yan Song, PhD, Chief Executive Officer of Link Health. It is important for Link Health to collaborate with companies that have strong therapeutic product portfolios and entrepreneurial management. This partnership with Bone Therapeutics is a direct result of our shared commitment to appreciate the enormous potential of cell therapy and regenerative medicine.

Pregene now has a flourishing portfolio of CAR-T cell therapy-based cancer treatments. Bone Therapeutics ALLOB provides anallogeneic, off-the-shelf cell therapy that expands our portfolio of cell therapies to include the sizable commercial potential of orthopedics,said Hongjian Li, Co-founder and Chief Executive Officer of Pregene. We expect to be able to leverage our extensive international cell and gene therapy experience to develop Bone Therapeutics ALLOB platform and subsequently launch products in China and Southeast Asian markets.

ALLOB, an allogeneic and off-the-shelf cell therapy product manufactured through a proprietary, scalable production process, consists of human bone-forming cells derived from cultured bone marrow mesenchymal stem cells of healthy adult donors. In preclinical studies ALLOB has shown to reduce healing time in a delayed-union fracture model by half, and has demonstrated good tolerability and signs of efficacy in two Phase IIa studies for two separate indications. The Companys randomized, placebo-controlled, double-blind Phase IIb clinical trial in patients with difficult tibial fractures has received approval from regulatory authorities in six of the seven planned European countries to date, and is expected to enroll the first patient later this year.

About Link Health Pharma Co., Ltd

Link Health is a leading Chinese pharmaceutical company based in Guangzhou, Southern China, focusing on the development of innovative drugs for unmet medical needs.

Link Health has created a highly professional team with diverse expertise in drug development, medical affairs and regulatory affairs. Leveraging deep understanding of China market, regulatory environment and strong network with global biopharmaceutical companies, Link Health is well positioned to bring innovative drugs to the market efficiently. The company has a drug development pipeline of 5 clinical stage assets and 1 under NDA reviewing in China.

The company has also established a fully owned subsidiary in Amsterdam, the Netherlands. The Dutch office builds and further strengthen collaborations with global pharma/biotech partners and research institutes.

About Pregene Biopharma Co., Ltd

Shenzhen Pregene Biopharma Co. Ltd is a leading enterprise in the cell and gene therapy field with the core technology for industrialization. The companys core team comes from well-known institutions and companies including the Academy of Military Medical Sciences, the University of Toronto, and the US FDA.

Pregene has established the gene editing platform, viral vector and cell production platform, nanobody selection platform and other small to pilot trial manufacturing system, with total investment over 100 million CNY. It has the laboratories and GMP plants for cell and gene therapy of over 10,000 square meter.

The company focuses on the research and development of cell and gene therapy drugs, and participated in the drafting the national standard Considerations for CAR-T Cell Quality Study and Non-clinical Evaluation issued by the National Institutes for Food and Drug Control in June 2018. The CAR-T cell therapy for the treatment of multiple myeloma have obtained NMPA IND clearance as the Class I new drug, which is the first in China and fastest in the world using the humanized single domain antibody in CAR construct, and phase I clinical trials are now in progress. Other pipelines such as CAR-T, TCR-T and mRNA drugs for tumors, autoimmune diseases and other indications are in the development at different stages. The company has broad development prospects with the abundant backup technologies.

Looking forward to the future, the company will build the core capacity in one-stop solution for cell and gene therapy drugs, and fulfill the Express of innovative medicine development from drug discovery to clinical products.

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and other diseases. The Company has a, diversified portfolio of cell and biologic therapies at different stages ranging from pre-clinical programs in immunomodulation to mid-to-late stage clinical development for orthopedic conditions, targeting markets with large unmet medical needs and limited innovation.

Bone Therapeutics is developing an off-the-shelf next-generation improved viscosupplement, JTA-004, which is currently in phase III development for the treatment of pain in knee osteoarthritis. Consisting of a unique combination of plasma proteins, hyaluronic acid a natural component of knee synovial fluid, and a fast-acting analgesic, JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain and inflammation. Positive phase IIb efficacy results in patients with knee osteoarthritis showed a statistically significant improvement in pain relief compared to a leading viscosupplement.

Bone Therapeutics core technology is based on its cutting-edge allogeneic cell therapy platform with differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs) which can be stored at the point of use in the hospital. Currently in pre-clinical development, BT-20, the most recent product candidate from this technology, targets inflammatory conditions, while the leading investigational medicinal product, ALLOB, represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells from healthy donors into bone-forming cells. These cells are produced via the Bone Therapeutics scalable manufacturing process. Following the CTA approval by regulatory authorities in Europe, the Company is ready to start the phase IIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process. ALLOB continues to be evaluated for other orthopedic indications including spinal fusion, osteotomy, maxillofacial and dental.

Bone Therapeutics cell therapy products are manufactured to the highest GMP standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available atwww.bonetherapeutics.com.

For further information, please contact:

Bone Therapeutics SAMiguel Forte, MD, PhD, Chief Executive OfficerJean-Luc Vandebroek, Chief Financial OfficerTel: +32 (0)71 12 10 00investorrelations@bonetherapeutics.com

For Belgian Media and Investor Enquiries:BepublicCatherine HaquenneTel: +32 (0)497 75 63 56catherine@bepublic.be

International Media Enquiries:Image Box CommunicationsNeil Hunter / Michelle BoxallTel: +44 (0)20 8943 4685neil.hunter@ibcomms.agency / michelle@ibcomms.agency

For French Media and Investor Enquiries:NewCap Investor Relations & Financial CommunicationsPierre Laurent, Louis-Victor Delouvrier and Arthur RouillTel: +33 (0)1 44 71 94 94bone@newcap.eu

For US Media and Investor Enquiries:LHA Investor RelationsYvonne BriggsTel: +1 310 691 7100ybriggs@lhai.com

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such persons officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

More:
Bone Therapeutics, Link Health and Pregene to develop and commercialize the ALLOB allogeneic bone cell therapy platform in China and Southeast Asia -...

Aziyo Biologics, Inc. is slated to price its IPO on Wednesday, October 7th.

From the prospectus:

"We are a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. From our proprietary tissue processing platforms, we have developed a portfolio of advanced regenerative medical products that are designed to be very similar to natural biological material. Our proprietary products, which we refer to as our Core Products, are designed to address the implantable electronic device/cardiovascular, orthopedic/spinal repair and soft tissue reconstruction markets, which represented a combined $3 billion market opportunity in the United States in 2019. To expand our commercial reach, we have commercial relationships with major medical device companies, such as Boston Scientific and Medtronic, to promote and sell some of our Core Products. We believe our focus on our unique regenerative medicine platforms and our Core Products will ultimately maximize our probability of continued clinical and commercial success and will create a long-term competitive advantage for us."

"We estimate that more than two million patients were either implanted with medical devices, such as pacemakers, defibrillators, neuro-stimulators, spinal fusion and trauma fracture hardware or tissue expanders for breast reconstruction, in the United States in 2019. This number is driven by advances in medical device technologies and an aging population with a growing incidence of comorbidities, including diabetes, obesity and cardiovascular and peripheral vascular diseases. These comorbidities can exacerbate various immune responses and other complications that can be triggered by a device implant."

"Our Core Products are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection. We believe that we have developed the only biological envelope, which is covered by a number of patents, that forms a natural, systemically vascularized pocket for holding implanted electronic devices. We have a proprietary processing technology for manufacturing bone regenerative products for use in orthopedic/spinal repair that preserves a cells ability to regenerate bone and decelerates cell apoptosis, or programmed cell death. We have a patented cell removal technology that produces undamaged extracellular matrices for use in soft tissue reconstruction. In pre-clinical and clinical studies, our products have supported and, in some cases, accelerated tissue healing, and thereby improved patient outcomes."

"COMPETITION: Our Core Products compete primarily with implantable electronic device envelopes and other cardiovascular repair products, other orthobiologics and human-derived acellular dermis products. The CanGaroo envelope competes with the synthetic envelope TYRX from Medtronic (NYSE:MDT). ProxiCor, Tyke and VasCure compete with bovine pericardium produced by numerous companies, including Gores Goretex and Terumos (OTCPK:TRUMF) Vascutek. FiberCel, ViBone and OsteGro V compete with other viable bone matrices, such as Smith & Nephews (NYSE:SNN)Bio4, MTFs Trinity ELITE, NuVasives (NASDAQ:NUVA) OsteoCel, Vivex Biologics VIA Graft and LifeNet Healths ViviGen. SimpliDerm competes primarily against human-derived acellular dermis matrix meshes, including AbbVies (NYSE:ABBV)AlloDerm, Surgalign Holdings (NASDAQ:SRGA)Cortiva, Strykers (NYSE:SYK) DermACELL andEthicons FlexHD. SimpliDerm also competes against animal-derived biological mesh products, such as AbbVies Strattice and Integras (NASDAQ:IART) SurgiMend, as well as various synthetic mesh products."

Go here to see the original:
Aziyo Biologics to price IPO on Oct. 7th; competitors include ABBV, MDT, SRGA and SYK - Seeking Alpha

WINNIPEG, AB, Oct. 5, 2020 /PRNewswire/ -Medicure Inc.("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a pharmaceutical company, announces that through its wholly-owned subsidiary, Medicure International Inc., it has entered into a License, Manufacture and Supply Agreement (the "Agreement") with Reliance Life Sciences Private Limited ("RLS") for a cardiovascular biosimilar (the "Product"). Medicure is responsible for the regulatory approval process for the Product. A biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an approved reference product. The Agreement grants an exclusive right to Medicure to market and sell the Product in the United States of America, Canada and the European Union.

"We are very pleased with the agreement we have reached with RLS. The Product fits well with Medicure's mission of being a significant cardiovascular company focused on the U.S. market." commented Dr. Albert Friesen, Chief Executive Officer for Medicure. "We look forward to the growth of our portfolio of cardiovascular products."

About Medicure Inc. Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT(tirofiban hydrochloride) injection and ZYPITAMAGTM (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. For more information on Medicure please visit http://www.medicure.com. For additional information about ZYPITAMAGTM, refer to the full Prescribing Information.

About Reliance Life Sciences Private Limited Reliance Life Sciences Private Limited (RLS) is part of the Promoter Group of Reliance Industries Limited. RLS is a research driven organization developing business opportunities in bio-therapeutics (plasma proteins, biosimilars and novel proteins), pharmaceuticals, regenerative medicine, clinical research services, and molecular medicine. The Reliance Group isIndia'slargest private sector enterprise, with annual revenues of$ 86 billion USD. The Group's flagship company, Reliance Industries Limited isIndia'slargest private sector company and a Fortune Global 100 company. RLS is a fully integrated life sciences industry player with in-house capabilities in research, pre-clinical and clinical development, process development, quality management, commercial-scale manufacturing, and marketing. For further information on Reliance Life Sciences please visithttp://www.rellife.com/

To be added to Medicure's e-mail list, please visit: http://medicure.mediaroom.com/alerts

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Information: Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes", "may", "plans", "will", "estimates", "continues", "anticipates", "intends", "expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-looking statements, include estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's future product revenues, the ability of AGGRASTATto provide benefits to COVID-19 patients, expected future growth in revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availability of financing on reasonable terms; results of current and future clinical trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the "Risk Factors" section of its Form 20F for the year ended December 31, 2019.

View original content:http://www.prnewswire.com/news-releases/medicure-announces-an-agreement-with-reliance-life-sciences-for-the-marketing-rights-of-a-cardiovascular-biosimilar-301145432.html

SOURCE Medicure Inc.

Read the original post:
Medicure announces an agreement with Reliance Life Sciences for the marketing rights of a cardiovascular biosimilar - BioSpace

Thanks to the advent of equity crowdfunding, theres never been a better time for retail investors seeking new opportunities. Innovative companies that may not have traditional venture capital backing can now market their solutions to a wider demographic. And thats the case with Cytonics. But its the promising nature of the treatment platform that has many excited about Cytonics stock.

Source: Shutterstock

Cytonics is a biotechnology firm specializing in regenerative medicine for osteoarthritis patients. According to Cytonics SeedInvest.com investor profile, over 27 million people in the U.S. suffer from arthritis-related pain, imposing a $180 billion burden on our health care system and economy.

However, this number is understated, according to the Centers for Disease Control and Prevention, which states that 32.5 million American adults suffer from osteoarthritis. Right there, the case for Cytonics stock theoretically improves by 20%.

Setting that aside, the osteoarthritis profile in this country makes this biotech firm a compelling equity crowdfunding opportunity. For instance, one of the risk factors for this condition is old age. As you know, the U.S. experienced a baby boom following the end of World War II to sometime in the early 1960s. But that increase in baby-making now means we have a massive population of older people.

Logically, this dynamic increases the probabilities of osteoarthritis, presenting a growing case for Cytonics stock. In addition, obesity is a risk factor because according to the CDC, Extra weight puts more stress on joints, particularly weight-bearing joints like the hips and knees.

You only need to go outside to see our national expanding waistline.

Although we can talk all day about the plentiful and still-expanding market size for osteoarthritis solutions, it wont mean a darn thing if the underlying science backing Cytonics stock was lacking. Fortunately, this biotech firm is all about the science.

What separates Cytonics from other therapies is the discovery of alpha-2-macroglobulin (A2M), which may hold the key for many osteoarthritis sufferers because multiple tests confirm this blood serum protein protects cartilage. Further, the presence of A2M may halt the progression of osteoarthritis.

Therefore, the catalyst behind Cytonics stock came from an idea: what if bioengineers can inject A2M at the source of trouble, providing both pain relief and preventative therapy? And thats exactly the concept here. Under a three-step process, Cytonics take blood from patients, run it through a centrifuge to increase the level of platelets, and then reinject the A2M-rich solution to the source of pain.

In this manner, patients can enjoy relief essentially through their own blood. However, the present technology of platelet-rich plasma injections may not produce enough A2M to restore damaged joints. This is where the second catalyst of Cytonics stock comes into play.

The biotech firm is presently developing a synthetic version of A2M called CYT-108. Based on its hypothesis, Cytonics believes that its synthetic version is more effective, perhaps between two to three times more effective than naturally occurring A2M.

Now, this is the key factor that has many excited about the potential of Cytonics stock. If the Food and Drug Administration approves CYT-108, this may be the only therapy that addresses osteoarthritis root cause, perhaps leading to a cure.

What lends credibility for the biotech firm is that its natural A2M therapy has treated over 7,000 people in the U.S., leading to encouraging results.

While the science of osteoarthritis treatments makes this equity crowdfunding opportunity distinct, its not without risks you must consider. As with all private investing ventures, youve got to do your due diligence. Remember, most startups fail this is just a harsh fact.

But experimental biotech firms are probably among the wildest investments. Yes, if a company passes advanced-stage clinical trials, the target security could fly to the moon. But such successes are rare, as evidenced by the wasteland of failed biotechs. In addition, you should keep in mind that for decades, the FDA has approved relatively few drugs/treatments.

To be fair, the platelet-rich plasma therapy which Cytonics technology is based off has few major demerits. Thats according to a 2018 study exploring the pros and cons of regenerative medicine and published by the National Institutes of Health. Still, under certain circumstances, PRP applications can result in injection-site morbidity, infection or injury to nerves or blood vessels. Scar tissue formation and calcification at the injection site have also been reported.

Also, the report notes that patients with compromised immune system or with predisposed diseases are more susceptible to infection at the injured area.

Are these acceptable risks for Cytonics stock? Possibly. Nevertheless, according to a study on platelet-rich plasma therapy for knee disorders, many methods have been utilized to treat osteoarthritis but with limited success. Plus, this report states that variables such as centrifugation prep work can negative the effectiveness of plasma-based regenerative therapies.

Im not trying to dissuade you from Cytonics stock. Rather, Im pointing out that theres a reason why successful therapies havent been found yet: this is a tough condition to address.

Personally, Im a gun shy regarding most biotech plays. There are so many variables involved, each one levering a possible negative impact. And I dont think Cytonics stock is any different in that sense.

However, the underlying science is very compelling. Thus, if you can handle the heat, plenty of justification exists for taking a shot. To learn more about this equity crowdfunding opportunity, please visit Cytonics SeedInvest profile.

On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.

A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare.

Investing through equity and real estate crowdfunding or asset tokenization requires a high degree of risk tolerance. Despite what individual companies may promise, theres always the chance of losing a portion, or the entirety, of your investment. These risks include:

1) Greater chance of failure2) Risk of fraudulent activity3) Lack of liquidity4) Economic downturns5) Dearth of investor education

Read more:Private Investing Risks

Originally posted here:
A Painless Future Provides the Incentive Behind Cytonics - InvestorPlace

HONG KONG Xian, China-based Yufan Biotechnologies Co. Ltd. has partnered with Pittsburgh-based Abound Bio Inc. to discover and develop antibodies directing CAR T cells against cancer targets.

The three-year partnership will see the two companies incorporate antibodies for novel cancer targets into the enhanced, HPK1 (hematopoietic progenitor kinase 1)-inhibited CAR T-cell platform, they said. The agreement covers 10 cancer targets, including difficult to treat solid tumors such as liver cancer, Abounds CEO John Mellors told BioWorld.

Although both companies declined to reveal financial details, Mellors said, I calculate that Yufans technology added to Abounds antibodies gives a value greater than two." Yufan declined to comment for the article, but CEO Yan Zhang said, "The partnership with Abound will improve CAR T-cell products for cancer therapy.

The two companies will also share expertise and any potential commercial upside, as well as inventorship and development rights. Yufan definitely benefits, both financially and non-financially, particularly via development rights in China, Mellors said.

The companies will conduct preclinical, then clinical testing of the new CAR T cells against solid tumors, with trials expected to start in the first or second quarter of 2021, Mellors said. They will target the greater China market initially, with the rest of the world to follow. No other firms have been targeted as future partners yet.

Academic roots

The partnership between Yufan and Abound started with an academic collaboration between the National Cancer Institute and Tsinghua University, based on the work led by the universitys professor of pharmaceutical science, Xuebin Liao, who co-founded Yufan along with Zhang. That work demonstrated that HPK1 promotes T-cell exhaustion through NFkB-Blimp1 activation, and that blocking HPK1, via either gene knockout or small-molecule inhibitors, improves CAR T-cell immunotherapy.

Yufan was founded in July 2016 as part of the Xi'an Hi-tech Industries Development Zone Central Organization Departments Thousand Talents program. It focuses on upstream technology development, services and antibody screening for immuno-oncology therapy. The company is developing CAR T cells with a deleted HKP1 gene to prevent cell exhaustion, with a first-in-human clinical study of the XYF-19 HPK1 knockout CD19 CAR T product currently underway in patients with relapsed or refractory CD19+ leukemia or lymphoma.

Other projects include CAR T-cell therapy, CAR T-cell GMP production, immune cell gene editing CRISPR/Cas9 technology, a phage antibody library, phage display technology, and the buildout of a human antibody screening platform. The company is currently collaborating with the Air Force Military Medical Universitys Xijing Hospital on an investigational CAR T-cell therapy.

Yufan plans to invest 100 million (US$14.72 million) to build manufacturing facilities for CAR T-cell therapies to treat refractory and relapsed leukemia and lymphoma and expects to generate annual sales of between 200 million to 400 million once those candidates reach market.

Across the Pacific, Abound is an early stage biotechnology company developing antibody-based biological therapeutics for cancer and infectious diseases.

One infectious disease that the company is concentrating on is COVID-19, with the number of global cases topping 35 million as of Oct. 5, according to Johns Hopkins University data. An Abound team led by Mellors and the companys chief scientific officer, Dimiter Dimitrov, discovered human monoclonal antibodies with neutralizing activity in the laboratory against SARS-CoV-2, the virus that causes COVID-19, from antibody libraries.

Although the antibodies have proved effective in low doses in mouse and hamsters, human trials have not yet started. However, the antibodies are ready for testing in CAR T cells in preclinical models, and we hope to rapidly progress to clinical studies, Mellors said.

The company is currently proceeding with production and clinical development for regulatory approval and commercialization in the MENA and ASEAN regions, clinching an agreement with Saudi-U.S. joint venture Saudivax earlier in the year.

The Yufan-Abound partnership also aims to tap the lucrative T-cell market, which was valued at $2.7 billion in 2017 and is expected to reach $8.21 billion in 2025, growing at a compounded annual growth rate (CAGR) of 14.9% between 2017 and 2025, according to Frost & Sullivans report Growth Opportunities in the Global Cell Therapy Market, Forecast to 2025.

Amendments in regulatory and reimbursement policies, as well as the implementation of conditional approval policies for regenerative medicine, will further drive the market by expediting product launches, Aarti Chitale, Frost & Sullivan senior research analyst for transformational health, wrote. Additionally, improvements in cell culturing techniques alongside the use of different stem cells such as adipose-derived stem cells, mesenchymal stem cells, and induced pluripotent stem cells will strengthen the market with superior treatment options for non-oncological conditions such as neurological, musculoskeletal, and dermatological conditions, she added.

See original here:
Yufan inks deal with Abound to develop antibodies directing CAR T cells against cancer targets - BioWorld Online

The Global Regenerative medicine Market size is projected to reach USD 55.67 Mn by 2026 from USD 13.56 Mn in 2018, at a CAGR of 23% during the forecast period.

AllTheResearch has added Latest Research Report on Regenerative medicine Market 2020 Future Growth Opportunities, Development Trends, and Forecast 2026. The Global Regenerative medicine Market market report cover an overview of the segments and sub-segmentations including the product types, applications, companies & regions. This report describes overall Regenerative medicine Market size by analyzing historical data and future projections.

Get Exclusive Sample Report on Regenerative medicine Market is available at https://www.alltheresearch.com/sample-request/232

Market Segmentation:

The report features unique and relevant factors that are likely to have a significant impact on the Regenerative medicine market during the forecast period. This report also includes the COVID-19 pandemic impact analysis on the Regenerative medicine market. This report includes a detailed and considerable amount of information, which will help new providers in the most comprehensive manner for better understanding. The report elaborates the historical and current trends molding the growth of the Regenerative medicine market

View complete Report, https://www.alltheresearch.com/report/232/Regenerative-medicine

The segmentation of the Regenerative medicine market has been offered on the basis of product type, application, Major Key Players and region. Every segment has been analyzed in detail, and data pertaining to the growth of each segment has been included in the analysis

Top Players Listed in the Regenerative medicine Market Report are

Based on type, report split into

Based on Application Regenerative medicine market is segmented into

Get Chance of 20% Extra Discount, If your Company is Listed in Above Key Players List;https://www.alltheresearch.com/speak-to-analyst/232

Impact of COVID-19: Regenerative medicine Market report analyses the impact of Coronavirus (COVID-19) on the Regenerative medicine industry. Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 180+ countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Regenerative medicine market in 2020

COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Get the Sample ToC to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies. https://www.alltheresearch.com/impactC19-request/232

Regenerative medicineMarket: Key Questions Answered in Report

The research study on the Regenerative medicinemarket offers inclusive insights about the growth of the market in the most comprehensible manner for a better understanding of users. Insights offered in the Regenerative medicinemarket report answer some of the most prominent questions that assist the stakeholders in measuring all the emerging possibilities.

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Contact Name: Rohit B.Email:[emailprotected]Phone: 1-888-691-6870

See the article here:
Regenerative medicine Market will Register a Significant CAGR During Period 2020-2026 | 23% CAGR| Know the Companies List Could Potentially Benefit or...

Oct. 5, 2020 11:30 UTC

GOLDEN, Colo.--(BUSINESS WIRE)-- Reven Holdings, Inc. (Reven) is a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment platforms for cancer, viral illnessesincluding COVID-19and inflammatory disorders.

Reven is planning to initiate a randomized, double-blind, placebo-controlled, multi-institutional clinical trial of its lead anti-inflammatory/anti-oxidant investigational drug product Rejuveinix (RJX) in the treatment of COVID-19. The upcoming clinical trial is designed to evaluate the safety and efficacy of RJX in COVID-19 patients.

Reven today announced that three new members with extensive experience and knowledge in clinical research and quality assurance have joined its multi-disciplinary team to work on the COVID-19 clinical project:

Nancy Oehlke has assumed the role of Manager of Regulatory Affairs and Quality Assurance. Nancy has 20+ years of experience in drug development, Good Manufacturing Practice (GMP) / Good Laboratory Practice (GLP) compliance, regulatory aspects of drug product manufacturing and testing, and clinical research.

Renae Townsend has assumed the role of Director of Clinical Operations and Jenny Daniels has assumed the role of Director of Clinical Quality Assurance. Both Renae and Jenny have 15+ years of Good Clinical Practice (GCP), clinical research and clinical monitoring experience.

These new team members will help us provide sponsor oversight for the services rendered by the clinical research organizations (CRO) and other vendors who will support our clinical RJX program and execution of the clinical trial. I am excited to welcome these very experienced new members to Reven. I look forward to the opportunity to work side by side with them as we try to diligently advance the clinical development of RJX, said Fatih Uckun, MD PhD, Chief Medical Officer and Chief Scientific Officer of Reven.

Our IND (Investigational New Drug) application package for COVID-19 is completed and we are planning to roll out our clinical program against COVID-19 in the coming month, said Michael Volk, Director and Chief Strategy Officer of Reven.

Our new team members each will have a very important role in our efforts aimed at evaluating the clinical impact potential of RJX, added Peter Lange, CEO of Reven.

About Rejuveinix (RJX) RJX is an intravenous (IV) formulation of a patented first-in-class pharmaceutical composition containing a specific mixture of anti-oxidant and anti-inflammatory ingredients that is being developed for more effective treatment of patients with inflammatory disorders, including COVID-19 patients with viral sepsis and acute respiratory distress syndrome (ARDS). The clinical safety and tolerability of RJX was confirmed in a recently completed double blind, placebo-controlled Phase 1 dose-escalation study in healthy volunteers (ClinicalTrials.gov Identifier: NCT03680105).

About Reven Holdings, Inc. Reven Holdings, Inc., a Delaware corporation, through its Golden/Colorado-based operating company Reven, LLC, is developing new drugs for difficult-to-treat diseases. As a clinical stage biopharmaceutical company, Revens overarching goal is to develop effective treatments for serious health conditions caused by infectious, inflammatory, cardiovascular, and metabolic diseases. Its lead product, RJX, is being developed as a treatment platform against complications of COVID-19, sepsis, cardiovascular diseases, and diabetes.

About Dr. Fatih Uckun, M.D., Ph.D, Chief Medical Officer of Reven. Dr. Uckun is an Active Member of the American Society for Clinical Investigation (ASCI), an honor society for physician-scientists, and an active member of several professional organizations. He earned his doctoral degrees at University of Heidelberg in Germany and completed his residency training in Pediatrics, fellowship training in Hematology/Oncology/Blood and Bone Marrow Stem Cell Transplantation, as well as postdoctoral research training in immunology and microbiology at the University of Minnesota in the US.

Dr. Uckun has more than 30 years of professional experience in developmental therapeutics and biopharmaceuticals in oncology/immuno-oncology as well as infectious diseases and immunology. In addition, Dr. Uckun has deep knowledge and 20+ years of experience in treatment of infectious diseases and their complications. In particular, he has extensive experience in viral, fungal, and bacterial infections of immunocompromised hosts, septic shock, ARDS as well as systemic capillary leak syndrome and cytokine release syndrome (CRS). Dr. Uckun served as a Defense Advanced Research Projects Agency (DARPA)-funded principal investigator and directed a universal virus neutralizer program project as part of a countermeasures initiative against viruses that can be used as bioweapons and therefore pose a biothreat for our national security. Prior to joining Reven, Dr. Uckun was a Vice President, Clinical Strategy Lead, Oncology-Hematology and Member of the COVID-19 Task Force at Worldwide Clinical Trials.

Dr. Uckun worked 11 years as a Professor of Bone Marrow Transplantation, Therapeutic Radiology-Radiation Oncology, Pharmacology, and Pediatrics as well as Director of the Biotherapy Institute at the University of Minnesota, where he became the first recipient of the Endowed Hughes Chair in Biotherapy. He worked 6 years as a Professor and Head of Translational Research in Leukemia and Lymphoma of the CCBD and a Principal Investigator of the Stem Cell-Regenerative Medicine Initiative at the at the University of Southern California. During that time, Dr. Uckun served as the Chair of the Biotargeting Working Group for the National Cancer Institute (NCI)s Nanotechnology Alliance in Cancer.

He has held executive positions in multiple biotechnology companies and has extensive regulatory experience. He has published more than 500 peer-reviewed papers, received numerous awards, and served as a member of several medical journal editorial boards and NIH grant review/special emphasis panels. Website: https://www.linkedin.com/in/fatihuckun/

Revens Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as may, on-track, expect, anticipate hope, vision, optimism, design, exciting, promising, will, conviction, estimate, intend, believe and similar expressions are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the companys product candidates and the potential use of the companys product candidates to treat various disease indications. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing market competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates, and unexpected litigation or other disputes. These risks are not exhaustive; the company faces known and unknown risks, including the risk factors described in the companys periodic SEC filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information regarding future events, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005298/en/

See more here:
Reven Strengthens Its Clinical Team With Three New Members - BioSpace

Global Nanotechnology in Medical Market report explores the Nanotechnology in Medical industry around the globe offers details about industry review, classification, meaning, and possibility along with key regions and countries. This research report delivers detailed insights on each and every aspect of the Nanotechnology in Medical Market.

Additionally, the research study divided the market on the basis of product types, application as well as end-user industries of Shooting Ranges.A 360 degree summarize of the competitive scenario of the Global Nanotechnology in Medical Market is presented by Reportspedia, The recent study on the Nanotechnology in Medical market Analysis report provides information about this industry with a thorough assessment of this business.

Sample Copy of This [emailprotected]:

https://www.reportspedia.com/report/others/2015-2027-global-nanotechnology-in-medical-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/64313#request_sample

Major Players in the Nanotechnology in Medical market are:

3MCytimmuneNovartisCamurusMerckAmgenAccessRocheCelgeneMitsui ChemicalsSmith and NephewPfizerDentsply International

Nanotechnology in Medical market growth has been segregated into the Americas, APAC, Europe, Middle East & Africa. The Nanotechnology in Medical market size is appropriately divided into pivotal segments in the report. A synopsis of the industry with regards to market size concerning remuneration and volume aspects along with the current Nanotechnology in Medical market shares scenario is also offered in the report.

Ask for [emailprotected]:

https://www.reportspedia.com/discount_inquiry/discount/64313

Types covered in the Nanotechnology in Medical industry are:

Nano MedicineNano DiagnosisOther

Applications covered in the report are:

HospitalsClinicsOthers

The study wanted to focus on key manufacturers, competitive landscape, and SWOT analysis for the Nanotechnology in Medical industry. Apart from looking into the geographical regions, the report concentrated on key trends and segments that are either driving the enlargement of the industry. Researchers have also focused on individual growth trends besides their contribution to the overall market.

This is probable to drive the Global Nanotechnology in Medical Market over the forecast period. This research report covers the market landscape and its progress prospects in the near future. After study key companies, the report focuses on the new entrant contributing to the enlargement of the market. Most companies in the Global Nanotechnology in Medical Market are currently adopted new technological trends in the market.

Inquiry Before [emailprotected]:

https://www.reportspedia.com/report/others/2015-2027-global-nanotechnology-in-medical-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/64313#inquiry_before_buying

Key highlights of the global Nanotechnology in Medical Market research report:

Some of the key questions answered in this Nanotechnology in Medical Market report:

Table of Contents: Nanotechnology in Medical Market

Chapter 1: Overview of Nanotechnology in Medical Market

Chapter 2: Global Market Status and Forecast by Regions

Chapter 3: Global Nanotechnology in Medical Market Status and Forecast by Types

Chapter 4: Global Nanotechnology in Medical industry Status and Forecast by Downstream Industry

Chapter 5: Nanotechnology in Medical industry Market Driving Factor Analysis

Chapter 6: Market Competition Status by Major Manufacturers

Chapter 7: Major Manufacturers Introduction and Market Data

Chapter 8: Upstream and Downstream Nanotechnology in Medical industry Analysis

Chapter 9: Cost and Gross Margin Analysis

Chapter 10: Marketing Status Analysis

Chapter 11: Nanotechnology in Medical industry Market Report Conclusion

Chapter 12: Research Methodology and Reference

Get ToC for the overview of the premium report @:

https://www.reportspedia.com/report/others/2015-2027-global-nanotechnology-in-medical-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/64313#table_of_contents

Here is the original post:
Nanotechnology in Medical Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2027 - The Daily Chronicle

New York, NY Aqua-Spark(the Fund), the first investment fund focused on sustainable aquaculture, announced an investment inShiok Meats(Shiok), the worlds first cell-based crustacean meat company based in Singapore. Shiok is the first cell-based meat company in South East Asia, and the first and only cell-based meat company working on shrimp. Their flagship product is a highly-anticipated cell-based shrimp, which offers clean, traceable alternatives to the shrimp farming industry.

Aqua-Spark is the lead investor in Shiok Meats $12.6M Series A round, which also includes investments from SEEDS Capital (the investment arm of Enterprise Singapore), Real Tech Fund (Japan), Irongrey (a Global tech investing family office based in Korea), Yellowdog Empowers Fund (South Korea), Ilshin Holdings Pte. Ltd (Singapore), Toyo Seikan Group Holdings, Ltd (Japan),Veg Invest Trust (USA), Makana Ventures (Singapore), AiiM Partners LP (USA), Beyond Impact (Europe), Kelvin Chan Siang Lin (Singapore), and Alex Payne and Nicole Brodeur (USA). The funds will contribute towards building the first-of-its-kind commercial pilot plant from which Shiok plans to launch its minced shrimp product in 2022. This puts Shiok on schedule to become the first company in the world to have a fully functioning commercial pilot plant for cell-based crustacean production.

Mike Velings and Amy Novogratz, co-founders of Aqua-Spark:

The cell-based animal protein industry has been on our radar for some time as once it is at scale it will have an enormous influence on food production efficiency, food safety, and the environment. As our first investment in cell-based seafood, Shiok Meats immediately stood out to us with their strong, female-led team and impressive milestones to-date. While weve invested in a number of technologies working to make shrimp farming more efficient, healthier, and less polluting, Shiok is the first company in our portfolio to focus on shrimp production. We are excited to help shape this novel and innovative industry, which we expect to have a huge impact on the future of seafood, while continuing to support sustainable aquaculture operations, inputs, and innovations across the value chain.

The shrimp market is a $50 billion market globally with Vietnam, Thailand, Indonesia, and India being the major producers of shrimp. While there are many farms and technologies improving shrimp farming, there is still work to be done. Much of what is currently on the market is raised in crowded factories/farms and treated with antibiotics, chemicals, and hormones. Conventional production processes often contribute to overfishing, excessive bycatch, misrepresentation, and mislabeling as well as contamination with effluents, heavy metals, and microplastics. This form of production is unsustainable and the sector strain will only increase as the population grows. Shiok is addressing this need and disrupting crustacean production to ensure people can eat clean shrimp, crab and lobster from a safe source. Clean meat production could reduce the industrys greenhouse gas emissions by 96 percent, energy consumption by 45 percent, land use by 99 percent, and water consumption by 96 percent.

Shiok Meats was founded in August 2018 by two stem cell scientists, Dr. Sandhya Sriram and Dr. Ka Yi Ling, with over 20 years of combined experience in the muscle, fat, and stem cell biology fields. Shioks mission is to produce clean, healthy, cruelty-free seafood. Their cell-based production process is non-GMO and chemical and antibiotic-free.

Dr. Sandhya Sriram, CEO and co-founder of Shiok Meats:

We are extremely excited to work in partnership with Aqua-Spark as we develop cell-based seafood and meats that are contributing towards a cleaner and healthier seafood industry and solving for the inefficiencies around global protein production. Aqua-Spark was the perfect partner to lead our Series A because they care deeply about funding companies that address planetary health and food security. With their help, we hope to become the global leader in cell-based crustaceans and seafood. We are pleased that Aqua-Spark supports our global impact vision and will be with us for the long haul.

Shiok stands out from other cell-based meat production companies because of their proprietary technology that isolates stem cells from shrimp, lobster, and crabthey are the first company to be able to do this for cell-based production at the moment. Once the stem cells are harvested, the shrimp, lobster, and crab meats are grown in nutrient-rich conditions, similar to that of a greenhouse. After four-to-six weeks, the cell-based seafood is exactly the same as its conventional counterpart but more sustainable, clean, and nutritious. Shioks patent-pending technology can grow crustaceans four times faster than conventional production.

The output of Shioks pilot plant will be frozen cell-based shrimp meat for dumplings and other shrimp-based dishes. Beyond cell-based shrimp, Shiok plans to launch shrimp flavouring paste and powder, fully-formed 3D shrimp, and cell-based lobster and crab products in the coming years.

To date, Aqua-Spark has now invested in 20 complementary companies, technologies, and inputs that are working toward the sustainable production of aquatic life.

About Aqua-Spark

Launched in 2011, Aqua-Spark is an investment fund with a mission to transform the global aquaculture industry into one that is healthier, more sustainable, and more accessible. They invest in aquaculture companies across the value chainspanning farming operations, alternative feed ingredients, disease-battling technology, and consumer-facing aquaculture products. These companies are solving some of the industrys big challenges while bringing returns that are comparable to todays traditional industry. The portfolio works as an ecosystem, with the companies agreeing to collaborate on optimal solutions, and working together toward this shared vision of a more efficient global aquaculture industry.

Since 2015, the fund has invested in 20 complementary SMEs. Thus far, Aqua-Spark has EUR 152 million in assets under management, dedicated to investments in elements of the aquaculture industry that will make fish farming sustainable. The goal of the fund is to ultimately make sustainability widespread and profitable enough that it becomes the only way to farm fish.

About Shiok Meats

Shiok Meats is a cell-based, clean meat company. It is the first of its kind in Singapore and South-East Asia with a mission to deliver delicious, clean, and healthy seafood by harvesting from cells instead of animals. Shiok Meats is working to bring cell-based crustacean meats (shrimp, crab, lobster) to the kitchen. Their meats are cruelty-free, healthy, and better for the environment with the same taste and texture and more nutrients than their traditional counterparts.

Go here to see the original:
Aqua-Spark Announces an Investment in Singapore-based Shiok Meats, the First Cell-Based Company to Produce Clean, Sustainable, Cruelty-Free Shrimp and...

Kaleido Biosciences Inc (KLDO) is around the top of the Biotechnology industry according to InvestorsObserver. KLDO received an overall rating of 62, which means that it scores higher than 62 percent of all stocks. Kaleido Biosciences Inc also achieved a score of 76 in the Biotechnology industry, putting it above 76 percent of Biotechnology stocks. Biotechnology is ranked 34 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Kaleido Biosciences Inc (KLDO) stock is lower by -2.62% while the S&P 500 is up 0.6% as of 1:15 PM on Thursday, Oct 1. KLDO is down -$0.29 from the previous closing price of $11.07 on volume of 311,178 shares. Over the past year the S&P 500 has risen 17.16% while KLDO is up 49.72%. KLDO lost -$2.62 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Kaleido Biosciences Inc (KLDO) Stock.

The rest is here:
Is Kaleido Biosciences Inc (KLDO) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

The latest report titled Global Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Status and Forecast 2020-2026 aims to enhance your decision-making ability in the business by providing knowledgeable insights related to the market and competitive landscape. The report recognizes vital facts, events, and possible variations in the global Nanoparticles in Biotechnology and Pharmaceuticals market. The report depicts valuable insights related to significant market trends driving the industry. It highlights key opportunities and challenges faced by market leaders while assessing their competitive setting and corporate strategies for the estimated timeline. The report also reveals drivers, trends, the market scope, profitability, demand status, uncertainties, and development forecast from 2020 to 2026 time-period.

The report covers SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. The research studies the global Nanoparticles in Biotechnology and Pharmaceuticals market competition, leading companies, industry environment, emerging opportunities, trends, and crucial segments in the market. Then the study encompasses company profiles, size, production value, product specifications, capacity, and 2020-2026 market shares occupied by each company. The global market size & trends are classified based on the types of products, application segments, and end-user. Each segment expansion is assessed together with the estimation of their growth in the upcoming period.

DOWNLOAD FREE SAMPLE REPORT: https://www.magnifierresearch.com/report-detail/23602/request-sample

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

Key Segments Studied In The Report:

For competitor segment, the report includes global key players of the market as well as some small players: Roche, GE Healthcare, Merck, Novartis, AMAG Pharmaceuticals, Amgen, Bausch & Lomb, Biogen, Celgene, Gilead, Ipsen, Leadiant Biosciences, nanoComposix, Pacira Pharmaceuticals, Pfizer, Shire,

Segment by product type, this report focuses on consumption, market share, and growth rate of the market in each product type and can be divided into:

Segment by application, this report focuses on consumption, market share, and growth rate of the market in each application and can be divided into: Biotechnology, Pharmaceutical,

The important geographical segments of the global Nanoparticles in Biotechnology and Pharmaceuticals market are as follows: North America (United States, Canada, Mexico), Asia-Pacific (China, Japan, South Korea, India, Australia, Indonesia, Thailand, Malaysia, Philippines, Vietnam), Europe (Germany, France, UK, Italy, Russia, Rest of Europe), Central & South America (Brazil, Rest of South America), Middle East & Africa (GCC Countries, Turkey, Egypt, South Africa, Rest of Middle East & Africa).

Production and consumption Analysis of The Global Nanoparticles in Biotechnology and Pharmaceuticals Market:

One part is about its production and the other part is about its consumption. On the basis of its production, the report analyzes the production, revenue, gross margin of its main manufacturers, and the unit price that they offer in different regions from 2015 to 2019. In terms of consumption, we analyze the consumption volume, consumption value, sale price, import, and export in different regions from 2015 to 2019. We also make a prediction of its production and consumption in the coming 2020-2026.

ACCESS FULL REPORT: https://www.magnifierresearch.com/report/global-nanoparticles-in-biotechnology-and-pharmaceuticals-market-size-23602.html

Key Report Pointers & Highlights:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Magnifier Research is a leading market intelligence company that sells reports of top publishers in the technology industry. Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Magnifier Research also specializes in analyzing hi-tech systems and current processing systems in its expertise. We have a team of experts that compile precise research reports and actively advise top companies to improve their existing processes. Our experts have extensive experience in the topics that they cover. Magnifier Research provides you the full spectrum of services related to market research, and corroborate with the clients to increase the revenue stream, and address process gaps.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.magnifierresearch.com

See the original post:
Global Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 Analysis, Types, Applications, Forecast and COVID-19 Impact Analysis 2026 - The...

Abeona Therapeutics Inc (ABEO) is around the bottom of the Biotechnology industry according to InvestorsObserver. ABEO received an overall rating of 34, which means that it scores higher than 34 percent of all stocks. Abeona Therapeutics Inc also achieved a score of 23 in the Biotechnology industry, putting it above 23 percent of Biotechnology stocks. Biotechnology is ranked 27 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 34 means the stock is more attractive than 34 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Abeona Therapeutics Inc (ABEO) stock has fallen -5.46% while the S&P 500 is up 1.25% as of 2:03 PM on Wednesday, Sep 30. ABEO is down -$0.06 from the previous closing price of $1.11 on volume of 4,933,979 shares. Over the past year the S&P 500 is higher by 14.86% while ABEO is down -53.95%. ABEO lost -$1.31 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Abeona Therapeutics Inc (ABEO) Stock.

More:
Is Abeona Therapeutics Inc (ABEO) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

FLORHAM PARK, N.J., Sept. 28, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDS Biotech or the Company) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced that its Chief Medical Officer, Lauren V. Wood, M.D. will present key data from the companys previously reported Phase 1 trial of PDS0101 and planned Phase 2 clinical studies in patients with advanced HPV-associated malignancies at the World Vaccine Congress, being held virtually September 28 October 1, 2020.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology platform. Versamune effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations, and assumptions and include statements regarding the proposed public offering and anticipated closing. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including market conditions, whether the proposed offering is completed, the satisfaction of customary closing conditions related to the proposed offering and the other factors described in PDS Biotechs filings with the SEC. The information in this release is provided only as of the date of this release, and PDS Biotech undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

Media & Investor Relations Contact:

Deanne RandolphPDS BiotechnologyPhone: +1 (908) 517-3613Email: drandolph@pdsbiotech.com

James SaliernoThe Ruth GroupPhone: +1 (646) 536-7028 / +1 (973) 255-8361Email: jsalierno@theruthgroup.com

The rest is here:
PDS Biotechnology to Present Results from its Phase 1 Trial of PDS0101 and the Phase 2 Clinical Strategy in Patients with Advanced HPV-Associated...

The 65 rating InvestorsObserver gives to Seelos Therapeutics Inc (SEEL) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 81 percent of stocks in the Biotechnology industry, SEELs 65 overall rating means the stock scores better than 65 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Seelos Therapeutics Inc (SEEL) stock is lower by -6.62% while the S&P 500 has risen 1.25% as of 1:21 PM on Wednesday, Sep 30. SEEL is lower by -$0.07 from the previous closing price of $1.04 on volume of 6,319,446 shares. Over the past year the S&P 500 has gained 14.86% while SEEL has risen 7.78%. SEEL lost -$0.75 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Seelos Therapeutics Inc (SEEL) Stock.

View post:
Is Seelos Therapeutics Inc (SEEL) a Winner in the Biotechnology Industry? - InvestorsObserver

Reports from Quince Market Insights adds to its database of reports of Global Microbioreactor System Market Share, Growth, Trends, and Expected Market Research Study. This report provides a strategic overview of the Global Microbioreactor System Market and the forecasted growth estimates for the future. The main purpose of this report is to help the consumer understand the market as a whole, its meanings and segmentation, market potential, influential trends, and the barriers that it is facing. The Global Microbioreactor System Market report points out national and global business prospects and competitive conditions for Microbioreactor System .

Sample Copy of This Report: https://www.quincemarketinsights.com/request-sample-66040?utm_source=Arshad/dc

Companies Covered: Sartorius, Applikon Biotechnology, Eppendorf, Pall Corporation, PARR, M2p-labs, INFORS HT, PBS Biotech, Sysbiotech, HiTec Zang

Market size estimation and forecasts were given based on a detailed research methodology tailored to the conditions of the demand for Global Microbioreactor System . The Global Microbioreactor System Market has been segmented : By Type (24 Parallel Bioreactors, 48 Parallel Bioreactors, Others), By Application (Pharma, Biotech, Food Industry, Scientific Research Institutes, Others). Strict research and review have been a significant part of the preparation of the study. Those who read the report will get a thorough understanding of the industry.

Microbioreactor System Market

Get ToC for the overview of the premium report @ https://www.quincemarketinsights.com/request-toc-66040?utm_source=Arshad/dc

Industry experts have reviewed and validated the data and information taken from reputable sources such as blogs, business annual reports, journals, and other documents. To offer a detailed picture of the facts and data, diagrams, graphs, pie charts, and other representations have been used. This augments the visual appeal of the report and makes it easier to understand. Major regions covered in the study include North America, Europe, Asia Pacific, Middle East & Africa, and South America.

Make an Enquiry for purchasing this Report @ https://www.quincemarketinsights.com/enquiry-before-buying-66040?utm_source=Arshad/dc

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact:

Quince Market Insights

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [emailprotected]

Web: https://www.quincemarketinsights.com

Read more:
Microbioreactor System Market 2020: What Are The New Innovations By Companies- Sartorius, Applikon Biotechnology, Eppendorf, Pall Corporation, PARR,...

Agricultural Biotechnology Market report puts across the idea of high-level analysis of major market segments and identification of opportunities. This information not only aids businesses in taking sound and proficient decisions but also helps decide the advertising, promotion, marketing and sales strategy more gainfully. Moreover, estimation of strategic options, suggestions of winning action plans and support to make critical bottom-line decisions is also provided by experienced and innovative industry experts. It supports in adjusting the production depending on the conditions of demand in the market which evades the wastage of goods. The market data analysed in this Agricultural Biotechnology Market report makes achieve the business goal and objective in predetermined time frame.

Few of the major competitors currently working in the global Agricultural Biotechnology market are:

Syngenta AG, Monsanto, DuPont, Performance Plants Inc., Global Bio-Chem Technology Group, and ADAMA Agricultural Solutions are some of the key players in this industry

Get Free Sample Report @ https://www.adroitmarketresearch.com/contacts/request-sample/113

A large-scale Agricultural Biotechnology Market report is of great importance for better understanding of the market which leads to high business growth. This market report has a chapter on the global market and all its associated companies with their profiles, which gives valuable data related to their outlook in terms of finances, product portfolios, investment plans, and marketing and business strategies. Agricultural Biotechnology Market research report provides important and meaningful market insights for the business by taking into consideration various factors. Thoroughly analysed market segmentation aspect provides a clear idea about the product consumption based on several factors ranging from type, application, deployment model, end user to geographical region.

Global Agricultural Biotechnology market is set to witness a healthy CAGR in the forecast period of 2019-2026. This rise in market value can be attributed to the surging adoption of AI and IoT along with the involvement of Agricultural Biotechnology vendors

Regional Analysis Includes:

*Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)*Europe (Germany, France, UK, Russia, and Italy etc.)*North America (the United States, Mexico, and Canada.)*South America (Brazil, Argentina, Columbia, etc.)*The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Table and Figures Covered in This Report:*Agricultural Biotechnology Market Overview, Scope, Status, and Prospect*Agricultural Biotechnology Market Competition by Manufacturers*Agricultural Biotechnology Market Capacity, Production, Revenue (Value) by Region*Agricultural Biotechnology Market Supply (Production), Consumption, Export, Import by Region*Agricultural Biotechnology Market Production, Revenue (Value), Price Trend by Type*Agricultural Biotechnology Market Analysis by Application*Agricultural Biotechnology Market Manufacturing Cost Analysis*Agricultural Biotechnology Market Industry Effect Factors Analysis*Agricultural Biotechnology Market Forecast*Agricultural Biotechnology Market Research Findings and Conclusion

Access Detailed Report at https://www.adroitmarketresearch.com/industry-reports/agricultural-biotechnology-market

What are the Recent Development of the Market?

Agricultural Biotechnology Market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to Agricultural Biotechnology Market.

Key Questions Answered:

*What is the size and CAGR of the global Agricultural Biotechnology Market?*What are the key driving factors of the most profitable regional market?*Which are the leading segments of the global market?*How will the global market advance in the coming years?*What are the main strategies adopted in the global market?*What is the nature of competition in the global market?*What growth impetus or acceleration market carries during the forecast period?*Which region may hit the highest market share in the coming era?*What trends, challenges, and barriers will impact the development and sizing of the market?

Still Any Query? Feel Free to Contact our Expert at https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/113

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a Markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable Market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Read more:
Agricultural Biotechnology Market 2020: by Region, Production, Consumption, Revenue, Market Share, Growth Rate Analysis and Forecast Till 2025 - The...

LOS ANGELES, United States:The report is an all-inclusive research study of the global Interferon market taking into account the growth factors, recent trends, developments, opportunities, and competitive landscape. The market analysts and researchers have done extensive analysis of the global Interferon market with the help of research methodologies such as PESTLE and Porters Five Forces analysis. They have provided accurate and reliable market data and useful recommendations with an aim to help the players gain an insight into the overall present and future market scenario. The Interferon report comprises in-depth study of the potential segments including product type, application, and end user and their contribution to the overall market size.

Get PDF Sample Copy of Report: (Including TOC, List of Tables & Figures, Chart) :https://www.qyresearch.com/sample-form/form/1638467/global-interferon-market

In addition, market revenues based on region and country are provided in the Interferon report. The authors of the report have also shed light on the common business tactics adopted by players. The leading players of the global Interferon market and their complete profiles are included in the report. Besides that, investment opportunities, recommendations, and trends that are trending at present in the global Interferon market are mapped by the report. With the help of this report, the key players of the global Interferon market will be able to make sound decisions and plan their strategies accordingly to stay ahead of the curve.

Competitive landscape is a critical aspect every key player needs to be familiar with. The report throws light on the competitive scenario of the global Interferon market to know the competition at both the domestic and global levels. Market experts have also offered the outline of every leading player of the global Interferon market, considering the key aspects such as areas of operation, production, and product portfolio. Additionally, companies in the report are studied based on the key factors such as company size, market share, market growth, revenue, production volume, and profits.

Key Players Mentioned in the Global Interferon Market Research Report: Roche, Anke Biotechnology, Bayer, Merck & Co, Tri-Prime, Kawin, Genzon Pharma, Novartis, Biogen, Merck KGaA, Zydus Cadila, Huaxin Biotechnology, Harbin Pharmaceutical

Global Interferon Market Segmentation by Product: Assay Kit, Analyzer

Global Interferon Market Segmentation by Application: , Hepatitis, Multiple Sclerosis, Others

The Interferon Market report has been segregated based on distinct categories, such as product type, application, end user, and region. Each and every segment is evaluated on the basis of CAGR, share, and growth potential. In the regional analysis, the report highlights the prospective region, which is estimated to generate opportunities in the global Interferon market in the forthcoming years. This segmental analysis will surely turn out to be a useful tool for the readers, stakeholders, and market participants to get a complete picture of the global Interferon market and its potential to grow in the years to come.

Key questions answered in the report:

Request for customization in Report:https://www.qyresearch.com/customize-request/form/1638467/global-interferon-market

Table of Contents:

1 Interferon Market Overview1.1 Interferon Product Overview1.2 Interferon Market Segment by Type1.2.1 Long-lasting Type1.2.2 Ordinary Type1.3 Global Interferon Market Size by Type (2015-2026)1.3.1 Global Interferon Market Size Overview by Type (2015-2026)1.3.2 Global Interferon Historic Market Size Review by Type (2015-2020)

1.3.2.1 Global Interferon Sales Market Share Breakdown by Type (2015-2026)

1.3.2.2 Global Interferon Revenue Market Share Breakdown by Type (2015-2026)

1.3.2.3 Global Interferon Average Selling Price (ASP) by Type (2015-2026)1.3.3 Global Interferon Market Size Forecast by Type (2021-2026)

1.3.3.1 Global Interferon Sales Market Share Breakdown by Application (2021-2026)

1.3.3.2 Global Interferon Revenue Market Share Breakdown by Application (2021-2026)

1.3.3.3 Global Interferon Average Selling Price (ASP) by Application (2021-2026)1.4 Key Regions Market Size Segment by Type (2015-2020)1.4.1 North America Interferon Sales Breakdown by Type (2015-2026)1.4.2 Europe Interferon Sales Breakdown by Type (2015-2026)1.4.3 Asia-Pacific Interferon Sales Breakdown by Type (2015-2026)1.4.4 Latin America Interferon Sales Breakdown by Type (2015-2026)1.4.5 Middle East and Africa Interferon Sales Breakdown by Type (2015-2026)1.5 Coronavirus Disease 2019 (Covid-19): Interferon Industry Impact1.5.1 How the Covid-19 is Affecting the Interferon Industry

1.5.1.1 Interferon Business Impact Assessment Covid-19

1.5.1.2 Supply Chain Challenges

1.5.1.3 COVID-19s Impact On Crude Oil and Refined Products1.5.2 Market Trends and Interferon Potential Opportunities in the COVID-19 Landscape1.5.3 Measures / Proposal against Covid-19

1.5.3.1 Government Measures to Combat Covid-19 Impact

1.5.3.2 Proposal for Interferon Players to Combat Covid-19 Impact 2 Global Interferon Market Competition by Company2.1 Global Top Players by Interferon Sales (2015-2020)2.2 Global Top Players by Interferon Revenue (2015-2020)2.3 Global Top Players Interferon Average Selling Price (ASP) (2015-2020)2.4 Global Top Manufacturers Interferon Manufacturing Base Distribution, Sales Area, Product Type2.5 Interferon Market Competitive Situation and Trends2.5.1 Interferon Market Concentration Rate (2015-2020)2.5.2 Global 5 and 10 Largest Manufacturers by Interferon Sales and Revenue in 20192.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Interferon as of 2019)2.7 Date of Key Manufacturers Enter into Interferon Market2.8 Key Manufacturers Interferon Product Offered2.9 Mergers & Acquisitions, Expansion 3 Global Interferon Status and Outlook by Region (2015-2026)3.1 Global Interferon Market Size and CAGR by Region: 2015 VS 2020 VS 20263.2 Global Interferon Market Size Market Share by Region (2015-2020)3.2.1 Global Interferon Sales Market Share by Region (2015-2020)3.2.2 Global Interferon Revenue Market Share by Region (2015-2020)3.2.3 Global Interferon Sales, Revenue, Price and Gross Margin (2015-2020)3.3 Global Interferon Market Size Market Share by Region (2021-2026)3.3.1 Global Interferon Sales Market Share by Region (2021-2026)3.3.2 Global Interferon Revenue Market Share by Region (2021-2026)3.3.3 Global Interferon Sales, Revenue, Price and Gross Margin (2021-2026)3.4 North America Interferon Market Size YoY Growth (2015-2026)3.4.1 North America Interferon Revenue YoY Growth (2015-2026)3.4.2 North America Interferon Sales YoY Growth (2015-2026)3.5 Asia-Pacific Interferon Market Size YoY Growth (2015-2026)3.5.1 Asia-Pacific Interferon Revenue YoY Growth (2015-2026)3.5.2 Asia-Pacific Interferon Sales YoY Growth (2015-2026)3.6 Europe Interferon Market Size YoY Growth (2015-2026)3.6.1 Europe Interferon Revenue YoY Growth (2015-2026)3.6.2 Europe Interferon Sales YoY Growth (2015-2026)3.7 Latin America Interferon Market Size YoY Growth (2015-2026)3.7.1 Latin America Interferon Revenue YoY Growth (2015-2026)3.7.2 Latin America Interferon Sales YoY Growth (2015-2026)3.8 Middle East and Africa Interferon Market Size YoY Growth (2015-2026)3.8.1 Middle East and Africa Interferon Revenue YoY Growth (2015-2026)3.8.2 Middle East and Africa Interferon Sales YoY Growth (2015-2026) 4 Global Interferon by Application4.1 Interferon Segment by Application4.1.1 Hepatitis4.1.2 Multiple Sclerosis4.1.3 Others4.2 Global Interferon Sales by Application: 2015 VS 2020 VS 20264.3 Global Interferon Historic Sales by Application (2015-2020)4.4 Global Interferon Forecasted Sales by Application (2021-2026)4.5 Key Regions Interferon Market Size by Application4.5.1 North America Interferon by Application4.5.2 Europe Interferon by Application4.5.3 Asia-Pacific Interferon by Application4.5.4 Latin America Interferon by Application4.5.5 Middle East and Africa Interferon by Application 5 North America Interferon Market Size by Country (2015-2026)5.1 North America Market Size Market Share by Country (2015-2020)5.1.1 North America Interferon Sales Market Share by Country (2015-2020)5.1.2 North America Interferon Revenue Market Share by Country (2015-2020)5.2 North America Market Size Market Share by Country (2021-2026)5.2.1 North America Interferon Sales Market Share by Country (2021-2026)5.2.2 North America Interferon Revenue Market Share by Country (2021-2026)5.3 North America Market Size YoY Growth by Country5.3.1 U.S. Interferon Market Size YoY Growth (2015-2026)5.3.2 Canada Interferon Market Size YoY Growth (2015-2026) 6 Europe Interferon Market Size by Country (2015-2026)6.1 Europe Market Size Market Share by Country (2015-2020)6.1.1 Europe Interferon Sales Market Share by Country (2015-2020)6.1.2 Europe Interferon Revenue Market Share by Country (2015-2020)6.2 Europe Market Size Market Share by Country (2021-2026)6.2.1 Europe Interferon Sales Market Share by Country (2021-2026)6.2.2 Europe Interferon Revenue Market Share by Country (2021-2026)6.3 Europe Market Size YoY Growth by Country6.3.1 Germany Interferon Market Size YoY Growth (2015-2026)6.3.2 France Interferon Market Size YoY Growth (2015-2026)6.3.3 U.K. Interferon Market Size YoY Growth (2015-2026)6.3.4 Italy Interferon Market Size YoY Growth (2015-2026)6.3.5 Russia Interferon Market Size YoY Growth (2015-2026) 7 Asia-Pacific Interferon Market Size by Country (2015-2026)7.1 Asia-Pacific Market Size Market Share by Country (2015-2020)7.1.1 Asia-Pacific Interferon Sales Market Share by Country (2015-2020)7.1.2 Asia-Pacific Interferon Revenue Market Share by Country (2015-2020)7.2 Asia-Pacific Market Size Market Share by Country (2021-2026)7.2.1 Asia-Pacific Interferon Sales Market Share by Country (2021-2026)7.2.2 Asia-Pacific Interferon Revenue Market Share by Country (2021-2026)7.3 Asia-Pacific Market Size YoY Growth by Country7.3.1 China Interferon Market Size YoY Growth (2015-2026)7.3.2 Japan Interferon Market Size YoY Growth (2015-2026)7.3.3 South Korea Interferon Market Size YoY Growth (2015-2026)7.3.4 India Interferon Market Size YoY Growth (2015-2026)7.3.5 Australia Interferon Market Size YoY Growth (2015-2026)7.3.6 Taiwan Interferon Market Size YoY Growth (2015-2026)7.3.7 Indonesia Interferon Market Size YoY Growth (2015-2026)7.3.8 Thailand Interferon Market Size YoY Growth (2015-2026)7.3.9 Malaysia Interferon Market Size YoY Growth (2015-2026)7.3.10 Philippines Interferon Market Size YoY Growth (2015-2026)7.3.11 Vietnam Interferon Market Size YoY Growth (2015-2026) 8 Latin America Interferon Market Size by Country (2015-2026)8.1 Latin America Market Size Market Share by Country (2015-2020)8.1.1 Latin America Interferon Sales Market Share by Country (2015-2020)8.1.2 Latin America Interferon Revenue Market Share by Country (2015-2020)8.2 Latin America Market Size Market Share by Country (2021-2026)8.2.1 Latin America Interferon Sales Market Share by Country (2021-2026)8.2.2 Latin America Interferon Revenue Market Share by Country (2021-2026)8.3 Latin America Market Size YoY Growth by Country8.3.1 Mexico Interferon Market Size YoY Growth (2015-2026)8.3.2 Brazil Interferon Market Size YoY Growth (2015-2026)8.3.3 Argentina Interferon Market Size YoY Growth (2015-2026) 9 Middle East and Africa Interferon Market Size by Country (2015-2026)9.1 Middle East and Africa Market Size Market Share by Country (2015-2020)9.1.1 Middle East and Africa Interferon Sales Market Share by Country (2015-2020)9.1.2 Middle East and Africa Interferon Revenue Market Share by Country (2015-2020)9.2 Middle East and Africa Market Size Market Share by Country (2021-2026)9.2.1 Middle East and Africa Interferon Sales Market Share by Country (2021-2026)9.2.2 Middle East and Africa Interferon Revenue Market Share by Country (2021-2026)9.3 Middle East and Africa Market Size YoY Growth by Country9.3.1 Turkey Interferon Market Size YoY Growth (2015-2026)9.3.2 Saudi Arabia Interferon Market Size YoY Growth (2015-2026)9.3.3 UAE Interferon Market Size YoY Growth (2015-2026) 10 Company Profiles and Key Figures in Interferon Business10.1 Roche10.1.1 Roche Corporation Information10.1.2 Roche Description, Business Overview and Total Revenue10.1.3 Roche Interferon Sales, Revenue and Gross Margin (2015-2020)10.1.4 Roche Interferon Products Offered10.1.5 Roche Recent Development10.2 Anke Biotechnology10.2.1 Anke Biotechnology Corporation Information10.2.2 Anke Biotechnology Description, Business Overview and Total Revenue10.2.3 Anke Biotechnology Interferon Sales, Revenue and Gross Margin (2015-2020)10.2.4 Roche Interferon Products Offered10.2.5 Anke Biotechnology Recent Development10.3 Bayer10.3.1 Bayer Corporation Information10.3.2 Bayer Description, Business Overview and Total Revenue10.3.3 Bayer Interferon Sales, Revenue and Gross Margin (2015-2020)10.3.4 Bayer Interferon Products Offered10.3.5 Bayer Recent Development10.4 Merck & Co10.4.1 Merck & Co Corporation Information10.4.2 Merck & Co Description, Business Overview and Total Revenue10.4.3 Merck & Co Interferon Sales, Revenue and Gross Margin (2015-2020)10.4.4 Merck & Co Interferon Products Offered10.4.5 Merck & Co Recent Development10.5 Tri-Prime10.5.1 Tri-Prime Corporation Information10.5.2 Tri-Prime Description, Business Overview and Total Revenue10.5.3 Tri-Prime Interferon Sales, Revenue and Gross Margin (2015-2020)10.5.4 Tri-Prime Interferon Products Offered10.5.5 Tri-Prime Recent Development10.6 Kawin10.6.1 Kawin Corporation Information10.6.2 Kawin Description, Business Overview and Total Revenue10.6.3 Kawin Interferon Sales, Revenue and Gross Margin (2015-2020)10.6.4 Kawin Interferon Products Offered10.6.5 Kawin Recent Development10.7 Genzon Pharma10.7.1 Genzon Pharma Corporation Information10.7.2 Genzon Pharma Description, Business Overview and Total Revenue10.7.3 Genzon Pharma Interferon Sales, Revenue and Gross Margin (2015-2020)10.7.4 Genzon Pharma Interferon Products Offered10.7.5 Genzon Pharma Recent Development10.8 Novartis10.8.1 Novartis Corporation Information10.8.2 Novartis Description, Business Overview and Total Revenue10.8.3 Novartis Interferon Sales, Revenue and Gross Margin (2015-2020)10.8.4 Novartis Interferon Products Offered10.8.5 Novartis Recent Development10.9 Biogen10.9.1 Biogen Corporation Information10.9.2 Biogen Description, Business Overview and Total Revenue10.9.3 Biogen Interferon Sales, Revenue and Gross Margin (2015-2020)10.9.4 Biogen Interferon Products Offered10.9.5 Biogen Recent Development10.10 Merck KGaA10.10.1 Company Basic Information, Manufacturing Base and Competitors10.10.2 Interferon Product Category, Application and Specification10.10.3 Merck KGaA Interferon Sales, Revenue, Price and Gross Margin (2015-2020)10.10.4 Main Business Overview10.10.5 Merck KGaA Recent Development10.11 Zydus Cadila10.11.1 Zydus Cadila Corporation Information10.11.2 Zydus Cadila Description, Business Overview and Total Revenue10.11.3 Zydus Cadila Interferon Sales, Revenue and Gross Margin (2015-2020)10.11.4 Zydus Cadila Interferon Products Offered10.11.5 Zydus Cadila Recent Development10.12 Huaxin Biotechnology10.12.1 Huaxin Biotechnology Corporation Information10.12.2 Huaxin Biotechnology Description, Business Overview and Total Revenue10.12.3 Huaxin Biotechnology Interferon Sales, Revenue and Gross Margin (2015-2020)10.12.4 Huaxin Biotechnology Interferon Products Offered10.12.5 Huaxin Biotechnology Recent Development10.13 Harbin Pharmaceutical10.13.1 Harbin Pharmaceutical Corporation Information10.13.2 Harbin Pharmaceutical Description, Business Overview and Total Revenue10.13.3 Harbin Pharmaceutical Interferon Sales, Revenue and Gross Margin (2015-2020)10.13.4 Harbin Pharmaceutical Interferon Products Offered10.13.5 Harbin Pharmaceutical Recent Development 11 Interferon Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis11.1 Interferon Key Raw Materials11.1.1 Key Raw Materials11.1.2 Key Raw Materials Price11.1.3 Raw Materials Key Suppliers11.2 Manufacturing Cost Structure11.2.1 Raw Materials11.2.2 Labor Cost11.2.3 Manufacturing Expenses11.3 Interferon Industrial Chain Analysis11.4 Market Opportunities, Challenges, Risks and Influences Factors Analysis11.4.1 Market Opportunities and Drivers11.4.2 Market Challenges11.4.3 Market Risks11.4.4 Porters Five Forces Analysis 12 Market Strategy Analysis, Distributors12.1 Sales Channel12.2 Distributors12.3 Downstream Customers 13 Research Findings and Conclusion 14 Appendix14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Author Details14.4 Disclaimer

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

See original here:
Interferon Market Growth, Projections, Analysis, Trends and Forecast 2026 | ( Roche, Anke Biotechnology, Bayer) - The Daily Chronicle